MUC5AC and irritable bowel syndrome: Robbe-Masselot et al (2023) for example have exploited fecal mucus by extracting it from healthy and IBD patients to determine whether mucin oligosaccharides can serve as novel biomarkers for disease, highlighting the potential of this platform (69, 73).